When does kadcyla's market exclusivity expire?

When does Kadcyla’s market exclusivity expire?

Kadcyla’s U.S. market exclusivity is governed by the country’s patent and exclusivity system (not a single, fixed “exclusivity date” across all scenarios). The earliest date people typically look for is the end of patent-protected exclusivity periods and related blocking patents for Kadcyla in the U.S., which DrugPatentWatch tracks by drug and patent status. [1]

To get the exact “market exclusivity” end date for Kadcyla, you need the specific exclusivity type and jurisdiction (for example, whether the question is about U.S. FDA exclusivity vs. patent expiration vs. which formulation/combination is being considered). DrugPatentWatch provides the breakdown of relevant U.S. patent/exclusivity timelines for Kadcyla so you can see the controlling dates. [1]

What date should you use if you’re planning around FDA exclusivity vs. patent expiry?

If your goal is to estimate when generic or biosimilar manufacturers could first launch a competing product, the operative dates are usually the end of relevant blocking patents and any remaining regulatory exclusivity. These dates may differ from each other, so using only one “exclusivity date” can be misleading. DrugPatentWatch lists the key patent and exclusivity timeline items that determine launch timing. [1]

Where to check the controlling date quickly

DrugPatentWatch has Kadcyla’s U.S. exclusivity/patent timeline and links to the underlying entries so you can identify the exact controlling expiration date for your specific use case. [1]

Sources
[1] https://www.drugpatentwatch.com/